ADMA Biologics Inc (ADMA) – What Are Investment Firms Thinking About This Stock?

ADMA Biologics Inc (NASDAQ:ADMA – Get Free Report) has been given an average recommendation of “Moderate Buy” by the six brokerages that are currently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $18.67.

Several equities research analysts recently issued reports on the company. Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a report on Monday, September 14th. Finally, Mizuho dropped their target price on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th.

View Our Latest Report on ADMA Biologics

Hedge Funds Weigh In On ADMA Biologics

Several large investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in shares of ADMA Biologics during the second quarter valued at $321,037,000. Dimensional Fund Advisors LP lifted its position in ADMA Biologics by 3.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 5,005,481 shares of the biotechnology company’s stock worth $45,101,000 after buying an additional 169,843 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of ADMA Biologics by 107.5% during the first quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company’s stock worth $36,019,000 after acquiring an additional 2,071,338 shares in the last quarter. Nantahala Capital Management LLC purchased a new position in ADMA Biologics in the second quarter valued at about $19,753,141. Finally, Ranger Investment Management L.P. acquired a new stake in shares of ADMA Biologics during the 2nd quarter valued at about $17,706,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Up 4.2%

NASDAQ ADMA opened at $11.75 on Friday. The stock has a market cap of $2.63 billion, a PE ratio of 16.79 and a beta of 0.70. ADMA Biologics has a fifty-two week low of $7.21 and a fifty-two week high of $20.46. The business has a 50 day moving average price of $9.97 and a two-hundred day moving average price of $11.07. The company has a quick ratio of 3.81, a current ratio of 6.97 and a debt-to-equity ratio of 0.49.

ADMA Biologics (NASDAQ:ADMA – Get Free Report) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.16. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%. The business had revenue of $124.39 million for the quarter, compared to analyst estimates of $125.34 million. During the same period in the previous year, the company earned $0.14 earnings per share. The company’s revenue for the quarter was up 2.0% compared to the same quarter last year. As a group, sell-side analysts predict that ADMA Biologics will post 0.78 EPS for the current fiscal year.

ADMA Biologics Company Profile

(Get Free Report)

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company’s activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.

ADMA’s portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.

Recommended Stories

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.